FindTrial
Sign In

Tusamitamab ravtansine

DRUG6 trials

Sponsors

Sanofi-Aventis Recherche & Developpement, Sanofi, Erasmus Medical Center

Conditions

Breast Cancer MetastaticCancerMetastatic Breast CancerMetastatic Gastric CancerMetastatic Lung CancerNeoplasmNon-small cell lung cancer metastaticNon-squamous Non-small Cell Lung Cancer

Phase 1

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
TerminatedNCT05429762
SanofiNeoplasm
Start: 2022-10-03End: 2024-04-10Updated: 2025-04-06

Phase 2

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
TerminatedNCT04659603
SanofiBreast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Start: 2021-03-29End: 2025-01-19Updated: 2025-10-01
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
TerminatedNCT05245071
SanofiNon-squamous Non-small Cell Lung Cancer
Start: 2022-06-01End: 2024-11-20Updated: 2025-08-29
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
WithdrawnNCT05703555
Erasmus Medical CenterMetastatic Breast Cancer, Metastatic Gastric Cancer, Metastatic Lung Cancer
Start: 2024-02-16End: 2024-02-16Updated: 2024-02-28
Open-label, Phase 2 study of tusamitamab ravtansine (SAR408701) combined with pembrolizumab and tusamitamab ravtansine (SAR408701) combined with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5-positive expression advanced/metastatic nonsquamous non-small-cell lung cancer (NSQ NSCLC)
CompletedCTIS2023-509115-84-00
Sanofi-Aventis Recherche & DeveloppementCancer
Start: 2021-05-12End: 2024-12-24Target: 3Updated: 2024-12-18

Phase 3

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors
CompletedCTIS2024-515101-26-00
Sanofi-Aventis Recherche & DeveloppementNon-small cell lung cancer metastatic
Start: 2020-08-21End: 2024-11-14Target: 1Updated: 2024-11-05